Pepcid 252-day Waxman/Hatch extension created by court has no statutory basis -- GPIA appeal brief.
Executive Summary
PEPCID 252-DAY WAXMAN/HATCH EXTENSION UNDER COURT RULING CHALLENGED by the Generic Pharmaceutical Industry Association in a brief submitted in the appeal of the consolidated case of Merck, Schering-Plough, Bracco and Roche v. FDA and the Patent & Trademark Office. Merck's Pepcid (famotidine) patent is one of 12 specifically at issue in the case, which seeks to overturn the PTO/FDA position that sponsors cannot add existing Waxman/Hatch patent extensions to the new 20-year-from-filing terms created by the General Agreement on Tariffs & Trade. The plaintiffs won the first round in the case when the Alexandria, Va. federal court ordered FDA to publish expiration dates as submitted by NDA holders ("The Pink Sheet" Oct. 23, 1995, T&G-1).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth